[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Calcimedica Inc (CALC)

Calcimedica Inc (CALC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,665
  • Shares Outstanding, K 15,798
  • Annual Sales, $ 0 K
  • Annual Income, $ -29,560 K
  • EBIT $ -22 M
  • EBITDA $ -22 M
  • 60-Month Beta 0.91
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.88
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.33
  • Most Recent Earnings $-0.45 on 08/11/26
  • Next Earnings Date 11/11/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.15
  • Number of Estimates 1
  • High Estimate $-0.15
  • Low Estimate $-0.15
  • Prior Year $-0.39
  • Growth Rate Est. (year over year) +61.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6189 +9.08%
on 08/13/26
1.0000 -32.49%
on 07/31/26
-0.0693 (-9.31%)
since 07/14/26
3-Month
0.5400 +25.02%
on 06/24/26
1.1500 -41.30%
on 07/01/26
-0.0049 (-0.72%)
since 05/14/26
52-Week
0.4606 +46.57%
on 03/02/26
7.2000 -90.62%
on 01/02/26
-1.9349 (-74.13%)
since 08/14/25

Most Recent Stories

More News
CalciMedica Reports Second Quarter 2026 Financial Results and Provides Clinical & Corporate Updates

Completed private placement financing of up to approximately $49 million to advance pulmonary hypertension program Auxora Phase 1b proof-of-concept data in pulmonary arterial hypertension (PAH) and...

CALC : 0.6751 (+2.71%)
CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints

FDA aligned on new-onset severe respiratory failure as the Phase 2b primary endpoint, with multi-organ failure and time to medically indicated discharge as key secondary endpoints

CALC : 0.6751 (+2.71%)
CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program

Proceeds expected to support a focused pulmonary hypertension strategy, including a Phase 1b proof-of-concept study evaluating Auxora™ in PAH, with data anticipated mid-2027, and advancement of oral...

CALC : 0.6751 (+2.71%)
CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data

FDA reviewed a protocol amendment and interim safety data from the KOURAGE trial evaluating Auxora in AKI patients

CALC : 0.6751 (+2.71%)
CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates

FDA feedback on the Auxora™ pivotal program in acute pancreatitis and potential future development in acute kidney injury expected in 2Q 2026

CALC : 0.6751 (+2.71%)
CalciMedica Reports 2025 Financial Results and Provides Clinical Updates

Internal and external reviews of all available safety data from the Phase 2 KOURAGE trial in acute kidney injury (AKI) did not identify evidence of a drug-related toxicity with Auxora™

CALC : 0.6751 (+2.71%)
CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation

Safety concern warrants reevaluation of study design, including enrollment criteria

CALC : 0.6751 (+2.71%)
CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) with respiratory failure; data expected in 1H 2026

CALC : 0.6751 (+2.71%)
CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension

Preclinical data support CRAC channel inhibitor, CM5480, as a potential first-in-class, differentiated therapy for pulmonary arterial hypertension (PAH), both as monotherapy and in combination with existing...

CALC : 0.6751 (+2.71%)
CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025

Treatment with Auxora significantly reduced IL-17–related inflammation in both kidney and lung, significantly increased glomerular filtration rate (GFR), and decreased renal injury in a rat model of...

CALC : 0.6751 (+2.71%)

Business Summary

CalciMedica Inc. is a clinical-stage biopharmaceutical company. It focused on developing therapies for life-threatening inflammatory diseases with high unmet need. CalciMedica Inc. is based in LA JOLLA, Calif.

See More

Key Turning Points

3rd Resistance Point 0.7446
2nd Resistance Point 0.7166
1st Resistance Point 0.6959
Last Price 0.6751
1st Support Level 0.6472
2nd Support Level 0.6192
3rd Support Level 0.5985

See More

52-Week High 7.2000
Fibonacci 61.8% 4.6255
Fibonacci 50% 3.8303
Fibonacci 38.2% 3.0351
Last Price 0.6751
52-Week Low 0.4606

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.